RebeccaArielleShatskyMD

Breast Cancer

Associate Professor of Medicine, Scientific Director Inflammatory and Triple-Negative Breast Cancer Program, Breast Medical Oncology Co Team Leader

Join to view full profile

Dr. Shatsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Shatsky's full profile

Already have an account?

Office
9400 Campus Point Dr, 3rd Floor #7329
La Jolla, CA 92037
Phone+1 858-249-3230

Fax+1 858-822-6136
Is this information wrong?

Summary

Breast Cancer Medical Oncologist specializing in the treatment of young patients, triple negative breast cancer, lobular breast cancer and advanced/metastatic disease. Associate Professor of Medicine at UC San Diego. Breast Medical Oncology Co-Team Leader.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2011 - 2014
Keck School of Medicine of the University of Southern CaliforniaClass of 2011, MD
University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology
Cornell UniversityBA

Certifications & Licensure

CA State Medical License Active through 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

San Diego Top Doctor 2023
San Diego Top Doctor San Diego Medical Society, 2022
San Diego Top Doctor San Diego County Medical Society, 2021
Excellence in Oncology Teaching Award UC San Diego School of Medicine, 2021
San Diego Top Doctor San Diego County Medical Association, 2019
Inductee Alpha Omega Alpha Honor Medical Society
Join now to see all

Clinical Trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer Start of enrollment: 2010 Mar 01
Recruiting
Phase 2
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC Start of enrollment: 2018 Dec 05
Recruiting
Phase 3
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Start of enrollment: 2022 Sep 08
Active, not recruiting
Phase 1
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Start of enrollment: 2022 Jul 20
Recruiting
Phase 3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Start of enrollment: 2022 Jul 25
Recruiting
Phase 3
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors Start of enrollment: 2022 Feb 15
Recruiting
Phase 1
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) Start of enrollment: 2022 Nov 28
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy Start of enrollment: 2023 Mar 31
Recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Endocrine and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer-Capivasertib-Fulvestrant: ASCO...
Shatsky, R. A., Harold J Burstein, Angela DeMichele, Lesley Fallowfield, Mark R Somerfield, N Lynn Henry, > ;Journal of Clinical Oncology. 2024 Apr 20
Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer.
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molino...> ;Breast Cancer Research. 2024 Mar 13
1 citations
A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic Her2-negative breast cancer.
Rebecca A Shatsky, Hemali Batra-Sharma, Teresa Helsten, Richard B Schwab, Emily I Pittman, Minya Pu, Elizabeth Weihe, Emanuela M Ghia, Laura Z Rassenti, Alfredo Molino...> ;Breast Cancer Research. 2024 Feb 26
4 citations
Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
Barbara A Parker, Rebecca A Shatsky, Richard B Schwab, Anne M Wallace, , Denise M Wolf, Gillian L Hirst, Lamorna Brown-Swigart, Laura J Esserman, Laura J van 't Veer, ...> ;Breast Cancer Research and Treatment. 2023 Jun 1
Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease p...
Harriet T Rothschild, A Jo Chien, Rachel C Jankowitz, Mark Jm Magbanua, Jason A Mouabbi, Julia Levine, Rita A Mukhtar, Shatsky, R. A., Rebecca A Shatsky> ;Journal of Clinical and Translational Science. 2023 Jan 1
Evaluating Cancer Pain Characteristics and Treatment Factors in the Emergency Department: A Retrospective Cohort Study.
Rishi Gupta, Vanessa Resley, Ayesha Khan, David R Li, Rebecca A Shatsky, Christopher J Coyne, Lin, L.> ;Journal of Palliative Care. 2022 Oct 1
2 citations
Procalcitonin as a Predictive Tool for Death and ICU Admission among Febrile Neutropenic Patients Visiting the Emergency Department.
Christopher J Coyne, Edward M Castillo, Rebecca A Shatsky, Theodore C Chan> ;Medicina. 2022 Jul 23
28 citations
Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update.
N Lynn Henry, Mark R Somerfield, Zoneddy Dayao, Anthony Elias, Kevin Kalinsky, Lisa M McShane, Beverly Moy, Ben Ho Park, Kelly M Shanahan, Priyanka Sharma, Rebecca Sha...> ;Journal of Clinical Oncology. 2022 Sep 20
2 citations
18F-FES PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive Breast Cancer: Two Representative Cases and Review of the Literature.
Sandhya Bodapati, Peter Abraham, Angela Chen, Denise Guilbault, Marin McDonald, Jennifer Matro, Rebecca Shatsky, Sebastian Obrzut> ;Tomography. 2022 Apr 7
17 citations
Comparison of Early- and Late-Stage Breast and Colorectal Cancer Diagnoses During vs Before the COVID-19 Pandemic.
Jade Zifei Zhou, Shelly Kane, Celia Ramsey, Melody Akhondzadeh, Ananya Banerjee, Rebecca Shatsky, Kathryn Ann Gold> ;JAMA Network Open. 2022 Feb 1
7 citations
Real-World Data From a Molecular Tumor Board: Improved Outcomes in Breast and Gynecologic Cancers Patients With Precision Medicine.
Lindsey M Charo, Ramez N Eskander, Jason Sicklick, Ki Hwan Kim, Hyo Jeong Lim, Ryosuke Okamura, Suzanna Lee, Rupa Subramanian, Richard Schwab, Rebecca Shatsky, Steven ...> ;JCO Precision Oncology. 2022 Jan 1
119 citations
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace, Erica String-Reasor, Judy C. Boughey, A. Jo Chien, Anthony D. Elias, Heather Beckwi...> ;Cancer Cell. 2021 Jul 12
505 citations
Genetic/familial high-risk assessment: Breast, ovarian, and pancreatic, version 2.2021
Mary B. Daly, Tuya Pal, Michael Berry, Saundra S. Buys, Patricia I. Dickson, Susan M. Domchek, Ahmed Elkhanany, Susan Hatters Friedman, Michael Goggins, Mollie L. Hutt...> ;Journal of the National Comprehensive Cancer Network. 2021 Jan 6
148 citations
Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy.
Shumei Kato, Ki Hwan Kim, Hyo Jeong Lim, Amélie Boichard, Mina Nikanjam, Elizabeth Weihe, Dennis John Kuo, Ramez N. Eskander, Aaron M. Goodman, Natalie Galanina, Paul ...> ;Nature Communications. 2020 Oct 2
4 citations
Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers
Rishi S. Gupta, Adam T. Hryniewicki, Gary M. Vilke, Rebecca Shatsky, Christopher J. Coyne, Roach, C., Colin Roach> ;The Journal of Emergency Medicine. 2020 May 28
379 citations
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adapt...
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai, Anne M. Wallace, A. Jo Chien, Andres Forero-Torres, Erin D. Ellis, HS Han, Amy S. Clark, Kat...> ;JAMA Oncology. 2020 May 1
275 citations
Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Robert A. Swarm, Judith A. Paice, Doralina L. Anghelescu, Madhuri Are, Justine Yang Bruce, Sorin Buga, Marcin Chwistek, Charles S. Cleeland, David S. Craig, Ellin Gaff...> ;Journal of the National Comprehensive Cancer Network. 2019 Aug 1
29 citations
Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies.
Rebecca Shatsky, Barbara A. Parker, Nam Bui, Teresa Helsten, Richard Schwab, Sarah Boles, Razelle Kurzrock> ;Molecular Cancer Therapeutics. 2019 May 1
42 citations
Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
Adam T. Hryniewicki, Claire T. Wang, Rebecca Shatsky, Christopher J. Coyne> ;The Journal of Emergency Medicine. 2018 Oct 1
38 citations
Application of the MASCC and CISNE Risk-Stratification Scores to Identify Low-Risk Febrile Neutropenic Patients in the Emergency Department
Christopher J. Coyne, Vivian Le, Jesse J. Brennan, Edward M. Castillo, Rebecca Shatsky, Karen Ferran, Stephanie K. Brodine, Gary M. Vilke> ;Annals of Emergency Medicine. 2017 Jun 1
26 citations
Afatinib in the treatment of breast cancer
Sara A. Hurvitz, Rebecca Shatsky, Nadia Harbeck> ;Expert Opinion on Investigational Drugs. 2014 Jun 12
19 citations
Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer
Parvin F. Peddi, Rebecca Shatsky, Sara A. Hurvitz> ;Cancer Treatment Reviews. 2014 Mar 1
6 citations
Multiplex PCR-Ligation Detection Reaction Assay for Simultaneous Detection of Drug Resistance and Toxin Genes from Staphylococcus aureus, Enterococcus faecalis, and En...
K. Granger, Mark Rundell, Maneesh Pingle, Rebecca Shatsky, Davise H. Larone, Linnie M. Golightly, Francis Barany, Eric D. Spitzer> ;Journal of Clinical Microbiology. 2010 Jan 1
31 citations
Multiplexed Identification of Blood-Borne Bacterial Pathogens by Use of a Novel 16S rRNA Gene PCR-Ligase Detection Reaction-Capillary Electrophoresis Assay
Maneesh Pingle, Kathleen Granger, Philip B. Feinberg, Rebecca Shatsky, Bram Sterling, Mark Rundell, Eric D. Spitzer, Davise H. Larone, Linnie M. Golightly, Francis Barany> ;Journal of Clinical Microbiology. 2007 Jun 1
Join now to see all

Journal Articles

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
Parker BA, Shatsky RA, Schwab RB, Wallace AM; I-SPY 2 Consortium; Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ., Breast Cancer Research and Treatment, 4/8/2023

Press Mentions

In Denial: When Patients Don’t Want to Believe They Have CancerAugust 26th, 2022
Oncternal Therapeutics Presents Clinical Data on Cirmtuzumab at SABCS 2019December 12th, 2019
ctDNA Makes Progress as an Early Treatment Indicator in Breast CancerMay 13th, 2019
Join now to see all

Grant Support

Integrated Machine-Learning Platform to Inform Precision Therapy in Underrepresented Triple-Negative Breast Cancer PatientsCalifornia Institute for the Advancement of Precision Medicine2019–2021
A Phase 1b pilot clinical trial of cirmtuzumab, an anti-ROR1 monoclonal antibody, in combination with paclitaxel for the treatment of patients with metastatic, or locally advanced, unresectable breastPadres Pedal the Cause2019–2021